| Grant number: | 16/13021-4 |
| Support Opportunities: | Scholarships in Brazil - Scientific Initiation |
| Start date: | August 01, 2016 |
| End date: | July 31, 2017 |
| Field of knowledge: | Biological Sciences - Biochemistry - Metabolism and Bioenergetics |
| Principal Investigator: | Céline Marques Pinheiro |
| Grantee: | Larissa Vedovato Vilela de Salis |
| Host Institution: | Hospital do Câncer de Barretos. Fundação Pio XII (FP). Barretos , SP, Brazil |
| Associated research grant: | 15/25351-6 - MCT1 as a target and response mediator in melanoma therapy, AP.JP |
Abstract In the context of the metabolic reprogramming of tumor cells (Warburg effect), a variety of proteins show enhanced expression, including monocarboxylate transporters (MCTs). Recently, MCT1 was identified as a major determinant of the sensitivity to 3- bromopyruvate (3-BP), one of the most promising inhibitors of glycolytic metabolism. Melanoma is the most aggressive form of skin cancer and studies have reported that mutations in BRAF gene are associated with an increased risk of mortality in patients with melanoma. Importantly, BRAF mutations induce the Warburg effect and this reprogramming of energy metabolism has been reported as a possible strategy for the treatment of melanomas. The aim of the present project is to assess the role of MCT1 as a mediator of response to 3-BP treatment as an antineoplastic agent for the treatment of melanomas. For this, the sensitivity of melanoma primary cultures to 3-BP will be evaluated and associated with the metabolic profile of the cells, particularly MCT1 expression. The metabolic profile of primary cultures will be associated, also, with common mutations in melanomas. (AU) | |
| News published in Agência FAPESP Newsletter about the scholarship: | |
| More itemsLess items | |
| TITULO | |
| Articles published in other media outlets ( ): | |
| More itemsLess items | |
| VEICULO: TITULO (DATA) | |
| VEICULO: TITULO (DATA) | |